Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2013 by Massachusetts General Hospital.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Massachusetts General Hospital
Information provided by (Responsible Party):
Scott Randall Plotkin, MD, PhD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00657202
First received: March 27, 2008
Last updated: March 4, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this research study is to determine if ranibizumab can prevent the growth of neurofibromas. We will also be collecting extra blood and serum samples to help us learn more about NF1. Ranibizumab is a drug that affects the development of blood vessels that feed tumors. It targets a substance in the body called VEGF (Vascular Endothelial Growth Factor). VEGF helps tumors to grow and survive by supporting the growth of blood vessels that bring nutrients to the tumor. VEGF is made by cancerous tumors and also by non-cancerous tumors such as neurofibromas.
| Condition | Intervention | Phase |
|---|---|---|
|
Neurofibromatosis Type 1 Cutaneous Neurofibromas |
Drug: Ranibizumab |
Phase 0 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Pharmacodynamics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Pilot Study of Ranibizumab (Lucentis) for Neurofibromas Associated With Neurofibromatosis 1 |
Resource links provided by NLM:
MedlinePlus related topics:
Neurofibromatosis
Drug Information available for:
Ranibizumab
Genetic and Rare Diseases Information Center resources:
Nerve Sheath Neoplasm
Neurofibroma
Neurofibromatosis
Neurofibromatosis Type 1
U.S. FDA Resources
Further study details as provided by Massachusetts General Hospital:
Primary Outcome Measures:
- Determine the effect of inhibiting VEGF signaling on tumor volume and tumor interstitial fluid pressure by local injection of ranibizumab into cutaneous neurofibromas. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To identify angiogenic molecules upregulated in neurofibromas treated with ranibizumab. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
| Enrollment: | 11 |
| Study Start Date: | March 2008 |
| Estimated Study Completion Date: | December 2013 |
| Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Ranibizumab |
Drug: Ranibizumab
Given as an injection into three cutaneous neurofibromas on day 1 of the study treatment.
Other Name: Lucentis
|
Detailed Description:
- Participants will receive one injection of ranibizumab into 3 tumors on their skin (one dose per tumor) on day 1 of treatment. One other tumor will be injected with normal saline solution. The saline solution-called a control-is necessary to determine whether injections (without medicine) can cause a tumor to shrink. Tumors will be measured and photographed prior to treatment. Ranibizumab tumors will be removed on days 8, 15, and 29; the saline treated tumor will be removed on day 29.
- Participants will come into the clinic once a week for a total of 4 weeks and then again on Days 35. 57 and 85 for post-treatment visits. Some of the following tests and procedures will be performed: physical examination (including photographs of tumors), review of current medications, vital signs, routine blood tests, serum chemistry blood tests, interstitial fluid pressure measurements and tumor samples.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients must have diagnosis of NF1 based on NIH criteria with two or more of the following characteristics: a) Six or more cafe-au-lait macules b) Skin fold freckling in the axilla or groin c) Optic pathway glioma d) Two or more Lisch nodules of the iris e) Distinctive bony lesions such as dysplasia of the sphenoid wing or of a long bone such as the tibia f) Two or more neurofibromas of any type or 1 or more plexiform neurofibroma g) First degree relative with NF1
- At least four cutaneous neurofibromas on skin exam with the following qualities: a) the lesion must be discrete by clinical exam and must be at least 5mm away from another skin tumor b) the lesion must be amenable to measurement with calipers with minimum dimension of 5mm and maximum dimension of 20mm c)the lesions cannot be located on the face, scalp, or groin and must be located in an area that can be photographed d) histologic confirmation of tumor type is not required in the setting of compatible clinical setting
- Must be willing to have treated CNF surgically removed during the study
- 18 years of age or older
- Normal organ and marrow function as described in the protocol
Exclusion Criteria:
- Pregnant or breast-feeding women
- Chemotherapy or radiotherapy within 6 weeks prior to entering the study
- Receiving any other investigational agent
- History of allergic reactions attributed to compounds of similar chemical or biologic composition as ranibizumab
- Hypertension that cannot be controlled by medications
- Known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhages in the past
- NCI CTCAE grade 3 hemorrhage within 4 weeks of starting the study treatment
- Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
- Uncontrolled intercurrent illness
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00657202
Please refer to this study by its ClinicalTrials.gov identifier: NCT00657202
Locations
| United States, Massachusetts | |
| Massachusetts General Hospital | |
| Boston, Massachusetts, United States, 02114 | |
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
| Principal Investigator: | Scott Plotkin, MD, PhD | Massachusetts General Hospital |
More Information
No publications provided
| Responsible Party: | Scott Randall Plotkin, MD, PhD, Associate Professor, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT00657202 History of Changes |
| Other Study ID Numbers: | 07-332 |
| Study First Received: | March 27, 2008 |
| Last Updated: | March 4, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Massachusetts General Hospital:
|
NF1 neurofibroma ranibizumab Lucentis |
Additional relevant MeSH terms:
|
Neurofibroma Neurofibromatoses Neurofibromatosis 1 Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Neoplasms Neoplasms by Histologic Type Neoplasms, Nerve Tissue Neoplastic Syndromes, Hereditary |
Nerve Sheath Neoplasms Nervous System Diseases Nervous System Neoplasms Neurocutaneous Syndromes Neurodegenerative Diseases Neuromuscular Diseases Peripheral Nervous System Diseases Peripheral Nervous System Neoplasms |
ClinicalTrials.gov processed this record on March 02, 2015